Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/29/23
End: 05/14/24
Due: 05/14/25
Phase: N/A
Priority: Normal
Start: 03/25/25
End: 07/14/28
Due: 07/14/29
Phase: N/A
Priority: Normal
Start: 05/25/25
End: 01/02/26
Due: 01/02/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase I Study of RC1416 Injection | NCT06067490 | Nanjing RegeneCore Biotech Co., Ltd. | user2@example.com | None | 2023-06-29 | 2024-05-14 | 2025-05-14 | - | - | 2025-07-14 |
| This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile. | NCT06756451 | Nanjing RegeneCore Biotech Co., Ltd. | user2@example.com | None | 2025-03-25 | 2028-07-14 | 2029-07-14 | - | - | 2025-07-14 |
| A Phase Ib Study of RC1416 Injection | NCT06911866 | Nanjing RegeneCore Biotech Co., Ltd. | user2@example.com | None | 2025-05-25 | 2026-01-02 | 2027-01-02 | - | - | 2025-07-14 |